Drug Profile
Research programme: RNAi therapeutics - SomaGenics
Alternative Names: Short hairpin RNAs - SomaGenics; shRNAs - SomaGenics; sshRNA®Latest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator SomaGenics
- Developer Arbutus Biopharma; Roche; SomaGenics
- Class Antivirals; Small interfering RNA
- Mechanism of Action RNA interference; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Hepatitis D
- Research Diabetic foot ulcer
- Discontinued Hepatitis C
Most Recent Events
- 22 Feb 2023 Preclinical development is ongoing in USA for Hepatitis-D
- 22 Feb 2023 Research is ongoing in USA for Diabetic foot ulcer
- 22 Feb 2023 Discontinued - Preclinical for Hepatitis C in USA (Parenteral) (SomaGeneics Pipeline, February 2023)